Scios offering raises $114 million

24 June 2001

Scios has announced the completion of its public offering of just over5.7 million shares of its common stock, including a 750,000 share over-allotment exercised by underwriters JP Morgan, Lehman Brothers and SG Cowen Securities Corp.

Net proceeds were approximately $114 million, and the firm said that the funds will be used for capital expenditures and costs associated with Natrecor (nesiritide) for the treatment of patients with acute congestive heart failure, which recently received a unanimous vote of support from the US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee (Marketletter June 4).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight